£495.00

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in Japan

Price data last checked 126 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£495 today · cheaper than every other day in the last 5 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 39 days • 39 data points (No recent data available)

Historical
Generating forecast...
£495.00 £470.25 £480.15 £490.05 £499.95 £509.85 £519.75 28 December 2025 06 January 2026 16 January 2026 25 January 2026 04 February 2026

Price Distribution

Price distribution over 39 days • 1 price levels

Days at Price
39 days 0 10 20 29 39 £495 Days at Price

Price Analysis

Most common price: £495 (39 days, 100.0%)

Price range: £495 - £495

Price levels: 1 different prices over 39 days

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
28 November 2022
Listed Since
08 December 2022

Similar Products You Might Like

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in China
99% match

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in China

£495.00 20 Mar 2026
The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in India
99% match

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in India

£515.00 04 Feb 2026
The 2023-2028 World Outlook for Guillain-Barre Syndrome Therapeutics
99% match

The 2023-2028 World Outlook for Guillain-Barre Syndrome Therapeutics

£795.00 11 Feb 2026
The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics for US Zip Codes
98% match

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics for US Zip Codes

£490.00 14 Feb 2026
The 2023-2028 Outlook for Intravenous Immunoglobulin for Guillain-Barre Syndromes for US Zip Codes
98% match

The 2023-2028 Outlook for Intravenous Immunoglobulin for Guillain-Barre Syndromes for US Zip Codes

£490.00 20 Feb 2026
The 2013-2018 Outlook for Lou Gehrig's Disease Drugs in India
95% match

The 2013-2018 Outlook for Lou Gehrig's Disease Drugs in India

£495.00 28 Jan 2026
The 2016-2021 Outlook for Multiple Sclerosis Therapeutics in the United States
95% match

The 2016-2021 Outlook for Multiple Sclerosis Therapeutics in the United States

£595.00 14 Jan 2026
The 2023-2028 Outlook for Enzyme Replacement Therapy for Gaucher Diseases in the United States
95% match

The 2023-2028 Outlook for Enzyme Replacement Therapy for Gaucher Diseases in the United States

£520.00 18 Feb 2026
The 2023-2028 Outlook for Peripheral Neuritis Treatments in China
95% match

The 2023-2028 Outlook for Peripheral Neuritis Treatments in China

£495.00 07 Jan 2026
The 2023-2028 Outlook for Peripheral Neuritis Treatments in India
95% match

The 2023-2028 Outlook for Peripheral Neuritis Treatments in India

£515.00 22 Jan 2026
Immunotherapies for Neurologic Diseases (Volume 214) (Handbook of Clinical Neurology, Volume 214)
95% match

Immunotherapies for Neurologic Diseases (Volume 214) (Handbook of Clinical Neurology, Volume 214)

Elsevier

£225.00 22 Jan 2026
The 2023-2028 Outlook for Enzyme Replacement Therapy for Gaucher Diseases for US Zip Codes
95% match

The 2023-2028 Outlook for Enzyme Replacement Therapy for Gaucher Diseases for US Zip Codes

£490.00 19 Feb 2026
The 2025-2030 World Outlook for Amyotrophic Lateral Sclerosis
95% match

The 2025-2030 World Outlook for Amyotrophic Lateral Sclerosis

Out of Stock 31 Jan 2026
The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in the United States
95% match

The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in the United States

£595.00 25 Jan 2026
The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in Japan
95% match

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in Japan

£495.00 05 Jan 2026
The 2023-2028 World Outlook for Gallium Nitride (GaN)-on-Silicon (Si) Renewables and Grids
95% match

The 2023-2028 World Outlook for Gallium Nitride (GaN)-on-Silicon (Si) Renewables and Grids

£795.00 08 Feb 2026
The 2013 Import and Export Market for Natural or Synthetic Glycosides and Their Salts, Ethers, Esters, and Other Derivatives in the United Kingdom
95% match

The 2013 Import and Export Market for Natural or Synthetic Glycosides and Their Salts, Ethers, Esters, and Other Derivatives in the United Kingdom

£234.00 01 Feb 2026
The 2023-2028 Outlook for Gram-Positive Bacterial Infections in India
95% match

The 2023-2028 Outlook for Gram-Positive Bacterial Infections in India

£515.00 16 Feb 2026
The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in Greater China
95% match

The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in Greater China

£595.00 23 Jan 2026
The 2023-2028 Outlook for Electric Guitars in Japan
95% match

The 2023-2028 Outlook for Electric Guitars in Japan

£495.00 16 Dec 2025
The 2023-2028 Outlook for Gamified Healthcare Solutions in the United States
95% match

The 2023-2028 Outlook for Gamified Healthcare Solutions in the United States

£520.00 30 Jan 2026
The 2013 Import and Export Market for Lysine, Its Esters and Salts Thereof, and Glutamic Acid and Its Salts in the United Kingdom
95% match

The 2013 Import and Export Market for Lysine, Its Esters and Salts Thereof, and Glutamic Acid and Its Salts in the United Kingdom

£246.00 26 Jan 2026
The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in Japan
95% match

The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in Japan

£595.00 06 Feb 2026
The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in the United States
95% match

The 2023-2028 Outlook for Beta Interferon Therapeutics for Multiple Sclerosis in the United States

£520.00 09 Jan 2026